News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Stephen V Liu: Disparities in Biomarker Testing and Targeted Therapy Use in Metastatic NSCLC
Stephen Liu/LinkedIn
May 23, 2025, 07:24

Stephen V Liu: Disparities in Biomarker Testing and Targeted Therapy Use in Metastatic NSCLC

Stephen V Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics and Associate Professor at the Georgetown Lombardi Comprehensive Cancer Center, posted on X:

“Flatiron analysis of 34,510 patients with NSCLC on biomarker testing JCO Oncology Practice by Sandip Patel.
Steady rise in biomarker testing: in 2023, 89% tested for EGFR and 88% for ALK. Not all receive targeted therapy though: only 84% of ALK+ receive an ALK TKI.”

Title: Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non–Small Cell Lung Cancer in the United States

Authors: Michael J. Dennis, Devin Abrahami, Maria Cecilia Vieira, Darrin Benjumea, Marley Boyd, Anran Shao, John Kelton, Sandip Pravin Patel

Read The Full Article at JCO Oncology.

Stephen V Liu: Disparities in Biomarker Testing and Targeted Therapy Use in Metastatic NSCLC

More posts featuring Stephen Liu.

Anran Shao cancer Darrin Benjumea Devin Abrahami JCO Oncology Practice John Kelton Lung cancer Maria Cecilia Vieira Marley Boyd Michael J. Dennis NSCLC OncoDaily Oncology Sandip Pravin Patel Stephen V Liu
Special Coverage
Science
May 23, 2025, 07:24
Stephen V Liu: Disparities in Biomarker Testing and Targeted Therapy Use in Metastatic NSCLC
Blog
May 23, 2025, 07:11
Rahul Banerjee Reacts to FDA ODAC News on Smoldering Myeloma Decision-Making
Blog
May 23, 2025, 07:02
Rebecca Shatsky: ASCO25 is Almost Here
Blog
May 23, 2025, 06:53
Jean-Baptiste Alberge: Genomic Landscape of Multiple Myeloma and Its Precursor Conditions
Blog
May 23, 2025, 06:34
Naveen Pemmaraju: SMAC Mimetics as Potential Cancer Therapeutics in Myeloid Malignancies
Blog
May 23, 2025, 06:26
Amer Zeidan Reflects on Anticipation for VERONA Trial Results in High-Risk MDS
Blog
May 23, 2025, 06:17
Join ASCO for the Social Media Meetup
Blog
May 23, 2025, 06:09
Stephen V Liu: Atezolizumab Plus Bevacizumab and Chemotherapy in Metastatic Nonsquamous NSCLC
Blog
May 23, 2025, 04:26
Angela Casini: Proud to See Our Radiopharmaceuticals Work Featured in Nature Biotechnology
Blog
May 23, 2025, 02:43
Richard Horton: This Year Is One of the Most Important for NCDs
Career
May 23, 2025, 01:50
Khalid El Bairi: Proud to See Aya Ikhelk Win Best Oral Presentation Award
Blog
May 22, 2025, 23:24
Aaron Sverdlov: Synergy in Cardio-Oncology China Visit Was a Fantastic Experience